These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 9781146)

  • 1. [Treatment of Crohn's disease with anti-TNF alpha].
    Lémann M
    Rev Prat; 1998 May; 48(10):1049-50. PubMed ID: 9781146
    [No Abstract]   [Full Text] [Related]  

  • 2. [Anti-TNF antibodies in the treatment of intestinal inflammatory disease].
    Hinojosa J
    Gastroenterol Hepatol; 2000 May; 23(5):250-7. PubMed ID: 10902280
    [No Abstract]   [Full Text] [Related]  

  • 3. Antibodies to tumor necrosis factor-alpha in the treatment of Crohn's disease.
    Brown SJ; Abreu MT
    Curr Opin Drug Discov Devel; 2005 Mar; 8(2):160-8. PubMed ID: 15782540
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease.
    Bauditz J; Lochs H; Schreiber S
    N Engl J Med; 1998 Jan; 338(5):334. PubMed ID: 9446035
    [No Abstract]   [Full Text] [Related]  

  • 5. Anti-TNF-alpha for treatment of amyloidosis associated with Crohn's disease.
    Fernández-Nebro A; Ureña I; Irigoyen MV; García-Vicuña R
    Gut; 2006 Nov; 55(11):1666-7; author reply 1667. PubMed ID: 17047117
    [No Abstract]   [Full Text] [Related]  

  • 6. [Clinical effectiveness of short-term administration of monoclonal antibody cA2 against tumor necrosis factor alpha in Crohn disease].
    Schreiber S; Koop I
    Z Gastroenterol; 1998 Apr; 36(4):349-51. PubMed ID: 9612932
    [No Abstract]   [Full Text] [Related]  

  • 7. [Treatment of Crohn's disease with anti TNF alpha antibodies--the experience in the Tel Aviv Medical Center].
    Dotan I; Yeshurun D; Hallak A; Horowitz N; Tiomny E; Reif S; Halpern Z; Rachmilewitz D
    Harefuah; 2001 Apr; 140(4):289-93, 368. PubMed ID: 11303390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Infliximab (Remicade) for Crohn's disease.
    Med Lett Drugs Ther; 1999 Feb; 41(1047):19-20. PubMed ID: 10076592
    [No Abstract]   [Full Text] [Related]  

  • 9. Fibrotic strictures and anti-TNF-alpha therapy in Crohn's disease.
    Sorrentino D; Terrosu G; Vadalà S; Avellini C
    Digestion; 2007; 75(1):22-4. PubMed ID: 17429204
    [No Abstract]   [Full Text] [Related]  

  • 10. Treatment of patients with Crohn's disease and concomitant chronic hepatitis C with a chimeric monoclonal antibody to TNF.
    Holtmann MH; Galle PR; Neurath MF
    Am J Gastroenterol; 2003 Feb; 98(2):504-5. PubMed ID: 12591081
    [No Abstract]   [Full Text] [Related]  

  • 11. Crohn's disease, TNF-alpha, and the leaky gut. The chicken or the egg?
    Hollander D
    Am J Gastroenterol; 2002 Aug; 97(8):1867-8. PubMed ID: 12190145
    [No Abstract]   [Full Text] [Related]  

  • 12. Tumor necrosis factor-alpha antagonism improves endothelial dysfunction in patients with Crohn's disease.
    Schinzari F; Armuzzi A; De Pascalis B; Mores N; Tesauro M; Melina D; Cardillo C
    Clin Pharmacol Ther; 2008 Jan; 83(1):70-6. PubMed ID: 17507924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-TNF therapies in rheumatoid arthritis, Crohn's disease, sepsis, and myelodysplastic syndromes.
    Raza A
    Microsc Res Tech; 2000 Aug; 50(3):229-35. PubMed ID: 10891888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term partial remission of autoimmune thrombocytopenia in a patient treated with the anti-tumor necrosis factor-alpha antibody infliximab for refractory fistulizing Crohn's disease.
    de Rossi TM; Krauss N; Voll RE; Nägel A; Weidenhiller M; Konturek PC; Hahn EG; Raithel M
    Digestion; 2008; 78(4):195-200. PubMed ID: 19122456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High serum tumor necrosis factor-alpha levels are associated with lack of response to infliximab in fistulizing Crohn's disease.
    Martínez-Borra J; López-Larrea C; González S; Fuentes D; Dieguez A; Deschamps EM; Pérez-Pariente JM; López-Vázquez A; de Francisco R; Rodrigo L
    Am J Gastroenterol; 2002 Sep; 97(9):2350-6. PubMed ID: 12358255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-TNF antibody in Crohn's disease--status of information, comments and recommendations of an international working group.
    Lochs H; Adler G; Beglinger C; Duchmann R; Emmrich J; Ewe K; Gangl A; Gasché C; Hahn E; Hoffmann P; Kaskas B; Malchow H; Pohl C; Raedler A; Renner E; Schölmerich J; Schreiber S; Stange E; Tilg H; Vogelsang H; Weigert N; Zeitz M
    Z Gastroenterol; 1999 Jun; 37(6):509-12. PubMed ID: 10427657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of anti-TNF-alpha therapy on spinal bone mineral density in patients with Crohn's disease.
    Pazianas M; Rhim AD; Weinberg AM; Su C; Lichtenstein GR
    Ann N Y Acad Sci; 2006 Apr; 1068():543-56. PubMed ID: 16831950
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Crohn's disease in common variable immunodeficiency: treatment with antitumor necrosis factor alpha.
    Nos P; Bastida G; Beltran B; Aguas M; Ponce J
    Am J Gastroenterol; 2006 Sep; 101(9):2165-6. PubMed ID: 16968516
    [No Abstract]   [Full Text] [Related]  

  • 19. Biologic therapy in Crohn's disease.
    Williams MD; Omran ML; Gordon GL
    Mo Med; 2009; 106(5):356-60. PubMed ID: 19902717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-TNF antibody treatment of Crohn's disease.
    van Deventer SJ
    Ann Rheum Dis; 1999 Nov; 58 Suppl 1(Suppl 1):I114-20. PubMed ID: 10577987
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.